As of 2025-12-12, the Intrinsic Value of Innocan Pharma Corp (INNO.CN) is 82.61 CAD. This INNO.CN valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 10.80 CAD, the upside of Innocan Pharma Corp is 664.90%.
The range of the Intrinsic Value is 19.16 - 1,501.14 CAD
Based on its market price of 10.80 CAD and our intrinsic valuation, Innocan Pharma Corp (INNO.CN) is undervalued by 664.90%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (6,719.60) - (1,315.19) | (2,199.40) | -20464.9% |
| DCF (Growth 10y) | (207,861.20) - (1,197,422.01) | (368,942.22) | -3416231.7% |
| DCF (EBITDA 5y) | 19.16 - 1,501.14 | 82.61 | 664.9% |
| DCF (EBITDA 10y) | 27,626.94 - 494,860.33 | 49,158.65 | 455072.7% |
| Fair Value | -2.94 - -2.94 | -2.94 | -127.24% |
| P/E | 2.45 - 4.61 | 3.06 | -71.7% |
| EV/EBITDA | (8.57) - 13.56 | 0.05 | -99.5% |
| EPV | (12.28) - (18.59) | (15.44) | -242.9% |
| DDM - Stable | (5.80) - (38.16) | (21.98) | -303.5% |
| DDM - Multi | 1,142.75 - 5,910.52 | 1,922.73 | 17703.1% |
| Market Cap (mil) | 48.60 |
| Beta | -0.10 |
| Outstanding shares (mil) | 4.50 |
| Enterprise Value (mil) | 48.60 |
| Market risk premium | 5.10% |
| Cost of Equity | 7.53% |
| Cost of Debt | 5.00% |
| WACC | 7.53% |